Pharma stock jumps 7% after acquires Roflumilast 500 mcg tablets from Breckenridge PharmaceuticalPharma stock jumps 7% after acquires Roflumilast 500 mcg tablets from Breckenridge Pharmaceutical

Introduction:

Leading pharmaceutical company has strengthened its respiratory portfolio by acquiring the USFDA-approved ANDA for Roflumilast 250 mcg and 500 mcg tablets. This acquisition aligns with its growth strategy, expanding its presence in the US market for COPD treatments.

Also Read: PSU stock in focus after it signs agreement with BSNL

Share price movement of Senores Pharmaceuticals:

On February 21, 2025, Senores Pharmaceuticals Ltd opened at ₹539.00, rising 0.84% from its previous close of ₹534.50. The stock reached a high of ₹574.00 (7.48%) and a low of ₹539.00. By 1:21 PM, it traded at ₹564.10 (5.61%), with a market cap of ₹2,606.17 crore.

Senores Pharmaceuticals Acquires ANDA for Roflumilast Tablets:

Senores Pharmaceuticals Limited, through its subsidiary Senores Pharmaceuticals, Inc., USA, has signed an agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Roflumilast 250 mcg and 500 mcg tablets from Breckenridge Pharmaceutical, Inc.

Roflumilast is used to reduce the risk of exacerbations in patients with severe Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis. The US market size for Roflumilast was approximately USD 32 million as of June 2024 and USD 46 million as of September 2024.

The acquisition is funded through the Initial Public Offering (IPO) proceeds raised by Senores Pharmaceuticals. This aligns with the IPO objectives stated in the company’s Red Herring Prospectus, strengthening its respiratory portfolio and expanding its presence in the US pharmaceutical market.

Recent news on Senores Pharmaceuticals:

As of January 23, 2025, Senores Pharmaceuticals Ltd reported a 35% year-on-year revenue increase to ₹106.4 crore, while net profit surged 142% to ₹17.2 crore. EBITDA rose 92% to ₹29.1 crore, with margins expanding to 27.3% in Q3 FY25.

Stock performance of Senores Pharmaceuticals for Period of 1 week and 1 month:

Senores Pharmaceuticals Ltd delivered a 3.65% return over the past week and a 7.08% gain in the last month, reflecting strong market confidence following its robust financial performance and strategic acquisition of Roflumilast ANDA in the U.S. market.

Also Read: Stock jumps after receiving order worth ₹128 Cr for water management and civil works in Kolkata

Shareholding pattern of Senores Pharmaceuticals:

Particulars	Dec 2024
Promoter	45.80%
FII	4.30%
DII	11.80%
Public	38.20%

About Senores Pharmaceuticals:

Senores Pharmaceuticals Ltd (NSE: SENORES) is a global research-driven pharmaceutical company specializing in complex generics, critical care injectables, and APIs. It serves regulated markets like the US, Canada, and the UK, focusing on high-quality, affordable pharmaceutical solutions.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.